GlycoVaxyn is a privately-funded company developing a portfolio of novel bio-conjugate vaccines against common severe bacterial infections produced with its unique, proprietary in vivoglycosylation platform. With this platform, the company can develop and produce immunogenic glycoproteins in a biological process that circumvents many of the challenges and uncertainties involved in currently/chemical used methods. In addition to the clinical stage Shigella vaccines, lead programs in preclinical stage are aimed at the prevention of hospital acquired Staphylococcusaureus infections, as well as pneumococcal invasive diseases. GlycoVaxyn has established collaborations with GlaxoSmithKline (GSK) and Janssen Pharmaceuticals. The company was founded in 2004 as a spin-out from the Federal Institute of Technology in Zurich (ETHZ) and is funded by a top-tier group of private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners as well as GSK.


Graziano Seghezzi

Graziano Seghezzi is Managing Partner at Sofinnova Partners which he joined in 2006. He seed funded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano als...